IMpower010: the first immunotherapy approved for resected NSCLC
Published 31/01/24
You are about to leave Roche4Med website. Links to external web pages are offered for your convenience. Roche Pharmaceuticals (Israel) Ltd. is not responsible for the content displayed on those pages.